Back to Newsroom

Vericel to Host Symposium on MACI Implant for Treating Articular Cartilage Defects in the Knee at AOSSM 2017 Annual Meeting

CAMBRIDGE, Mass., July 13, 2017 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, announced today that the company is hosting a symposium on the  MACI® (autologous cultured chondrocytes on porcine collagen membrane) implant for treating articular cartilage defects in the knee at the American Orthopedic Society for Sports Medicine’s 2017 Annual Meeting.